RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mendus AB (publ) Stock

Mendus AB (publ) Employees 2024

Mendus AB (publ) Employees

11

Ticker

IMMU.ST

ISIN

SE0005003654

WKN

A1W59F

In 2024, Mendus AB (publ) employed 11 people, a 0% change from the 11 number of employees in the previous year.

Mendus AB (publ) Aktienanalyse

What does Mendus AB (publ) do?

Immunicum AB is a biopharmaceutical company based in Stockholm, Sweden. It was founded in 2002 and has been working on developing innovative cancer therapies. The company aims to fight cancer cells in the body by targeting the activation of the body's immune system. Immunicum's business model is based on developing therapies that utilize allogeneic cell therapy. This involves using cells from donors to support specific processes in the body. Immunicum focuses on using dendritic cells as a model to specifically activate the body's immune system and fight cancer cells. The company has various divisions involved in the value chain of cancer therapy. One important area is the research and development of immunotherapies based on allogeneic cell therapy. Dendritic cells in particular are studied and further developed to enhance their effectiveness in fighting cancer. Another important division of Immunicum is clinical development, which involves conducting clinical trials to test and demonstrate the efficacy of the developed therapies in controlled studies. The results can then be used to seek approval for the therapies from regulatory authorities. Commercial development is another crucial area for Immunicum, involving the marketing and sale of the developed therapies. The company works closely with partners in the pharmaceutical industry to distribute the therapies worldwide and make them accessible to patients. Currently, the key product of Immunicum is the medication ilixadencel, which is a therapy based on allogeneic cell therapy that activates dendritic cells. Ilixadencel is being developed and tested as a treatment option for patients with renal cell carcinoma and glioblastoma. The medication is currently in clinical development and has already shown promising results in early studies. In addition to ilixadencel, Immunicum is also working on other products developed based on allogeneic cell therapy. This includes therapies for other types of cancer such as liver cancer and pancreatic cancer. The company has also achieved promising results in this area. Overall, Immunicum is an innovative biotech company aiming to develop new and effective cancer therapies. By specifically activating the body's immune system, their goal is to fight cancer cells and improve the quality of life for patients. The company has already made promising developments in this field and continues to work on improving the effectiveness of its therapies. Mendus AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Mendus AB (publ)'s Employee Base

Mendus AB (publ)'s employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Mendus AB (publ)'s operational capacity and future potential.

Year-to-Year Comparison

Assessing Mendus AB (publ)'s employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Mendus AB (publ)'s employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Mendus AB (publ)’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Mendus AB (publ) stock

How many employees does Mendus AB (publ) have this year?

Mendus AB (publ) has 11 undefined employees this year.

How many employees did Mendus AB (publ) have compared to the previous year?

Compared to the previous year, Mendus AB (publ) had 0% more employees.

What impact did the number of employees have on the company Mendus AB (publ)?

The number of employees has a direct impact on the efficiency and productivity of Mendus AB (publ). A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Mendus AB (publ)?

The number of employees can also have an impact on investors of Mendus AB (publ), as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Mendus AB (publ) affect the company?

An increase in equity of Mendus AB (publ) can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Mendus AB (publ)'s equity affect the company?

A reduction in equity of Mendus AB (publ) can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Mendus AB (publ)?

Some factors that can influence the equity of Mendus AB (publ) include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Mendus AB (publ) so important for investors?

The equity of Mendus AB (publ) is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Mendus AB (publ) influence the company?

The number of employees at Mendus AB (publ) can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Mendus AB (publ) evolved in recent years?

In recent years, the number of employees at Mendus AB (publ) has changed by 0.

How many employees does Mendus AB (publ) currently have?

Mendus AB (publ) currently has 11 undefined employees.

Why is the number of employees important for investors of Mendus AB (publ)?

The number of employees is important for investors of Mendus AB (publ) as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Mendus AB (publ) take to change the number of employees?

To change the number of employees, Mendus AB (publ) can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Mendus AB (publ) pay?

Over the past 12 months, Mendus AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mendus AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Mendus AB (publ)?

The current dividend yield of Mendus AB (publ) is .

When does Mendus AB (publ) pay dividends?

Mendus AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mendus AB (publ)?

Mendus AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Mendus AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mendus AB (publ) located?

Mendus AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mendus AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mendus AB (publ) from 10/2/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Mendus AB (publ) pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Mendus AB (publ) in the year 2023?

In the year 2023, Mendus AB (publ) distributed 0 SEK as dividends.

In which currency does Mendus AB (publ) pay out the dividend?

The dividends of Mendus AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mendus AB (publ)

Our stock analysis for Mendus AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mendus AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.